Aperçu des produits pour anti-ROS1 (ROS1) Anticorps

Full name:: anti-C-Ros Oncogene 1 , Receptor tyrosine Kinase Anticorps (ROS1)

Chez www.anticorps-enligne.fr sont 189 C-Ros Oncogene 1 , Receptor tyrosine Kinase (ROS1) Anticorps de 16 de différents fournisseurs disponibles. De plus, nous expédions ROS1 Kits (11) et ROS1 Protéines (10) et beaucoup plus de produits pour cette protéine. Un total de 215 ROS1 produits sont actuellement listés.

Synonymes:: c-ros, c-ros-1, MCF3, ROS, Ros-1, ROS1C

afficher tous les anticorps	Gène	GeneID	UniProt
	ROS1	6098	P08922
	ROS1	25346	Q63132
	ROS1	19886	Q78DX7
Afficher toutes les espèces Afficher tous les synonymes

Réactivités les plus populaires pour anti-ROS1 (ROS1) Anticorps

Sélectionnez vos espèces et l'application

anti-Human ROS1 Anticorps:

anti-Rat (Rattus) ROS1 Anticorps:

anti-Mouse (Murine) ROS1 Anticorps:

Tous anti-ROS1 Anticorps disponible

Vous arrivez à notre recherche pré-filtrée.

Pathways pertinentes pour anti-ROS1 Anticorps

Signalisation RTK

Plus produit pour ROS1 Anticorps

anti-ROS1 Anticorps mieux référencés

Human Polyclonal ROS1 Primary Antibody pour ELISA, WB - ABIN4242203 : Shiffman, Ellis, Rowland, Malloy, Luke, Iakoubova, Pullinger, Cassano, Aouizerat, Fenwick, Reitz, Catanese, Leong, Zellner, Sninsky, Topol, Devlin, Kane: Identification of four gene variants associated with myocardial infarction. dans American journal of human genetics 2005 (PubMed)

Plus d’anticorps contre ROS1 partenaires d’interaction

Human C-Ros Oncogene 1 , Receptor tyrosine Kinase (ROS1) interaction partners

The frequencies of ALK, ROS1 and RET (Montrer RET Anticorps) rearrangements are low in non-adenocarcinoma NSCLC patients. And their clinical characteristics are similar to those in lung adenocarcinoma. Fusions of the above 3 genes are not prognostic factor for non-adnocarcinoma NSCLC patients.
Compared with ROS1-negative advanced NSCLCs,ROS1-rearranged advanced NSCLCs were associated with a younger age at presentation. ROS1 rearrangements were not significantly associated with sex, smoking history, drinking history and metastatic sites.
ROS1 rearrangement was detected in 1.1% of CCA patients. Although rare, conduct of clinical trials using ROS1 inhibitors in these genetically unique patients is warranted.
For intra-hepatic cholangiocarcinomas (IHCC)patients, ROS1, ALK and c-MET expression levels have prognostic significance on clinical outcomes. Although this finding may require further validation, it has led to proposal of a new stratification or enriched biomarker for future phase III trial of anti-EGFR (Montrer EGFR Anticorps) therapy in IHCC
Polymorphisms rs1333049 and rs10757278 are associated with SCD (Montrer SCD Anticorps) in men and rs499818 in the women aged over 50 years.
Overcome crizotinib resistance in a ROS1-rearranged cancer.
The ROS1 S1986Y/F and ALK C1156Y mutations are homologous and displayed similar sensitivity patterns to ALK/ROS1 TKIs.
Given the results from the ROS1 cohort of the clinical trial PROFILE 1001, crizotinib represents a new treatment option and the first approved therapy for patients with metastatic non-small cell lung cancer whose tumors are ROS1 positive. Crizotinib demonstrated efficacy irrespective of prior treatment status.
ROS1 rearrangements rarely overlap with alterations in EGFR, KRAS, ALK, or other targetable oncogenes in NSCLC.
Durable benefits with pemetrexed-based therapies in RET (Montrer RET Anticorps)-rearranged lung cancers are comparable with ALK- and ROS1-rearranged lung cancers. When selecting therapies for patients with RET (Montrer RET Anticorps)-rearranged lung cancers, pemetrexed-containing regimens should be considered.

Mouse (Murine) C-Ros Oncogene 1 , Receptor tyrosine Kinase (ROS1) interaction partners

GPX1-dependent alterations in oxido-reductive stress promote ROS1 activation and mediate vascular remodeling.
Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins.
c-ros and its ligand may be necessary for differentiation of epithelia I and II in mouse.

ROS1 profil antigène

Antigen Summary

This proto-oncogene, highly-expressed in a variety of tumor cell lines, belongs to the sevenless subfamily of tyrosine kinase insulin receptor genes. The protein encoded by this gene is a type I integral membrane protein with tyrosine kinase activity. The protein may function as a growth or differentiation factor receptor.

Alternative names and synonyms associated with ROS1

ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) anticorps
ROS proto-oncogene 1 , receptor tyrosine kinase (Ros1) anticorps
Ros1 proto-oncogene (Ros1) anticorps

c-ros anticorps
c-ros-1 anticorps
MCF3 anticorps
ROS anticorps
Ros-1 anticorps
ROS1C anticorps

Protein level used designations for ROS1

c-Ros receptor tyrosine kinase , proto-oncogene c-Ros , proto-oncogene c-Ros-1 , proto-oncogene tyrosine-protein kinase ROS , receptor tyrosine kinase c-ros oncogene 1 , transmembrane tyrosine-specific protein kinase , v-ros UR2 sarcoma virus oncogene homolog 1 , v-ros avian UR2 sarcoma virus oncogene homolog 1 , Ros1 proto-oncogene , c-ros-1 , heart - derived c - ros - 1 proto - oncogene , proto-oncogene c-ros

GENE ID	SPECIES
6098	Homo sapiens
25346	Rattus norvegicus
396192	Gallus gallus
19886	Mus musculus

Fournisseurs de qualité sélectionnés pour anti-ROS1 (ROS1) Anticorps

Avez-vous cherché autre chose?

Tel:	+1 877 302 8632
Fax:	+1 888 205 9894 (Toll-free)
E-Mail:	orders@anticorps-enligne.fr

Show all anti-C-Ros Oncogene 1 , Receptor tyrosine Kinase (ROS1) Anticorps with Pubmed References

Human C-Ros Oncogene 1 , Receptor tyrosine Kinase (ROS1) interaction partners

Mouse (Murine) C-Ros Oncogene 1 , Receptor tyrosine Kinase (ROS1) interaction partners

Antigen Summary

Alternative names and synonyms associated with ROS1

Protein level used designations for ROS1